Endocrine Disrupting Activities of the Flavonoid Nutraceuticals Luteolin and Quercetin

Hormones and Cancer

Volumn 4, Issue 5, 2013, Pages 293-300

  Nordeen, Steven K ^a   Bona, Betty J ^a   Jones, David N ^a   Lambert, James R ^a   Jackson, Twila A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTOKERATIN 5; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LUCIFERASE; LUTEOLIN; PROGESTERONE; PROGESTERONE RECEPTOR; QUERCETIN;

ARTICLE; BREAST CANCER; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG INDUSTRY; DRUG MARKETING; ENDOCRINE FUNCTION; ENDOMETRIUM CANCER; ENZYME ACTIVITY; HORMONE INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; ENDOCRINE DISRUPTORS; FEMALE; HUMANS; LUTEOLIN; MODELS, MOLECULAR; QUERCETIN; RECEPTORS, PROGESTERONE;

EID: 84884130896     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0150-1     Document Type: Article

References (47)

1. Ramos S (2002) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52: 507-526.
2. Zern Tosca L, Fernandez ML (2005) Cardioprotective effect of dietary polyphenols. J Nutr 135: 2291-2294.
3. Nijveldt RJ, van Nood E, van Hoorn DEC, Boelens PG, van Norren K, van Leeuwen PAM (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74: 418-425.
4. Seelinger G, Merfort I, Wölfle U, Schempp CM (2008) Anti-carcinogenic effects of the flavonoid luteolin. Molecules 13: 2628-2651.
5. López-Lázaro M (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9: 31-59.
6. Press M, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP (2002) Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 67: 799-813.
7. Nordeen SK, Blanka K, Lawler-Heavner J, Barber DA, Edwards DP (1989) A quantitative comparison of dual control of a hormone response element by progestins and glucocorticoids in the same cell line. Mol Endocrinol 3: 1270-1278.
8. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Barbera DV, Sartorius CA (2013) Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer 4: 36-49.
9. Wilson VS, Kathy Bobseine L, Gray Jr. E (2004) Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 81: 69-77.
10. Ishiwata I, Ishiwata C, Soma M, Arai J, Ishikawa H (1984) Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesterone receptors. Gynecol Oncol 17: 281-290.
11. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
12. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193.
13. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461.
14. Madauss KP, Grygielko ET, Deng S-J, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD (2007) A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 21: 1066-1081.
15. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
16. Aninye IO, Berg KC, Mollo AR, Nordeen SK, Wilson EM, Shapiro DJ (2012) 8-Alkylthio-6-thio-substituted theophylline analogues as selective progesterone receptor antagonists. Steroids 77: 659-601.
17. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovica A, Rohan TE, Yasmmen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684-1692.
18. Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Woman Study. Lancet 362: 419-427.
19. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA (2011) Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 128: 45-55.
20. Zhou P, Li L-P, Luo S-Q, Jiang H-D, Zeng S (2008) Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J Agric Food Chem 56: 296-300.
21. Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N (1998) Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 438: 220-224.
22. Li L-P, Jiang H-D, Wu H, Zeng S (2005) Simultaneous determination of luteolin and apigenin in dog plamsa by RP-HPLC. J Pharm Biomed Anal 37: 615-620.
23. Moyer DL, Felix JC (1998) The effects of progesterone and progestins on endometrial proliferation. Contraception 57: 399-403.
24. Felix JC, Farahmand S (1997) Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle. Contraception 55: 19-22.
25. Ferenczy A, Bertrand G, Gelfand MM (1979) Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 133: 859-867.
26. Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, Bagchi MK, Bagchi IC (2011) The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 331: 912-916.
27. Xing N, Chen Y, Mitchell SH, Young CYF (2001) Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22: 409-414.
28. Williams SP, Sigler PB (1998) Atomic structure of progesterone complexed with its receptor. Nature 393: 392-396.
29. Raaijmakers HCA, Versteegh JE, Uitdehaag JCM (2009) The x-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J Biol Chem 284: 19572-19579.
30. Shutt DA (1976) The effects of plant estrogens on animal reproduction. Endeavour 35: 110-113.
31. Livingston AL (1978) Forage plant estrogens. J Toxicol Environ Health 4: 301-324.
32. Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HHS (1975) Potential value of plants as antifertility agents. II. J Pharm Sci 64: 717-754.
33. Verdeal K, Ryan DS (1979) Naturally-occurring estrogens in plant foodstuffs: a review. J Food Prot 42: 577-583.
34. Martin PM, Horwitz KB, Ryan DS, McGuire WL (1978) Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103: 1860-1867.
35. Farmakalidis EJ, Hathcock JN, Murphy PA (1985) Oestrogenic potency of genistein and daidzin in mice. J Food Prot 42: 577-583.
36. Miksicek RJ (1993) Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 44: 37-43.
37. Le Bail JC, Varnat F, Nicolas JC, Habrioux G (1998) Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett 130: 209-216.
38. van der Woude H, ter Veld MGR, Jacobs N, van der Saag PT, Murk AJ, Rietjens IMCM (2005) The stimulation of cell proliferation by quercetin is mediated by the estrogen receptor. Mol Nutr Food Res 49: 763-771.
39. Ise R, Han D, Takahashi Y, Terasaka S, Inoue A, Tanji M, Kiyama R (2005) Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett 579: 1732-1740.
40. Galluzzo P, Martini C, Bulzomi P, Leone S, Bolli A, Pallottini V, Marino M (2009) Quercetin-induced apoptotic cascade in cancer cells: antioxidant versus estrogen receptor α-dependent mechanisms. Mol Nutr Food Res 53: 699-708.
41. Lin FM, Chen L-R, Lin E-H, Ke F-C, Chen H-Y, Tsai M-J, Hsiao P-W (2007) Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 28: 2521-2529.
42. Willemsen P, Scippo M-L, Kausel G, Figueroa J, Maghuin-Rogister G, Martial JA, Muller M (2004) Use of reporter cell lines for detection of endocrine-disrupter activity. Anal Bioanal Chem 378: 655-663.
43. Scippo M-L, Argiris C, van De Weerdt C, Muller M, Willemsen P, Martial J, Maghuin-Rogister G (2004) Recombinant human estrogen, androgen, and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem 378: 664-669.
44. Toh MF, Sohn J, Chen SN, Yao P, Bolton JL, Burdette JE (2012) Biological characterization of non-steroidal progestins from botanicals used for women's health. Steroids 77: 765-773.
45. Rosenberg RS, Grass L, Jenkins DJA, Kendall CWC, Diamandis EP (1998) Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. Biochem Biophys Res Commun 248: 935-939.
46. Mafuvadze B, Benakanakere I, López-Perez FR, Besch-Williford C, Ellersieck MR, Hyder SM (2011) Apigenin prevents development of medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res 4: 1316-1324.
47. Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM (2012) Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer 3: 160-171.